Abstract
Protein-Protein Interactions (PPIs) that are part of the costimulatory and coinhibitory (immune checkpoint) signaling are critical for adequate T cell response and are important therapeutic targets for immunomodulation. Biologics targeting them have already achieved considerable clinical success in the treatment of autoimmune diseases or transplant recipients (e.g., abatacept, belatacept, and belimumab) as well as cancer (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab). In view of such progress, there have been only relatively limited efforts toward developing small-molecule PPI inhibitors (SMPPIIs) targeting these cosignaling interactions, possibly because they, as all other PPIs, are difficult to target by small molecules and were not considered druggable. Nevertheless, substantial progress has been achieved during the last decade. SMPPIIs proving the feasibility of such approaches have been identified through various strategies for a number of cosignaling interactions including CD40-CD40L, OX40-OX40L, BAFFR-BAFF, CD80-CD28, and PD-1-PD-L1s. Here, after an overview of the general aspects and challenges of SMPPII-focused drug discovery, we review them briefly together with relevant structura...Continue Reading
Citations
May 12, 2020·EMBO Molecular Medicine·Zhenzhen FanLiang Chen
May 28, 2020·International Journal of Molecular Sciences·Eun-Hye KimHideyuki Miyatake
Jun 21, 2020·Biology of Reproduction·Daniel S Johnston, Erwin Goldberg
Aug 4, 2020·Journal of Leukocyte Biology·Chloe M McKee, Rebecca C Coll
May 13, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Damir BojadzicPeter Buchwald
Sep 11, 2019·Diabetologia·Damir Bojadzic, Peter Buchwald
Dec 17, 2019·Biomedical Research·Tadashi AshizawaYasuto Akiyama
Jun 28, 2019·Frontiers in Pharmacology·Peter Buchwald
Mar 11, 2020·Nature Chemical Biology·Tianshu XiaoBing Chen
Jan 9, 2021·PloS One·Samuel EgieyehBurtram Fielding
Dec 29, 2020·Computational and Structural Biotechnology Journal·Andrea BerardiGiovanna Musco
Oct 4, 2020·Diabetes & Metabolism·Natalie YoussefAssaad A Eid
Jan 13, 2021·International Journal of Molecular Sciences·Serena VittorioLaura De Luca
Sep 28, 2020·Journal of Autoimmunity·Leonard H CalabreseAllan D Kirk
Mar 3, 2021·Chemical Communications : Chem Comm·Marijn N MaasJasmin Mecinović
Nov 30, 2019·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jamie L ShirleyRoland W Herzog
Feb 24, 2021·Nature Communications·Jang-June ParkChris B Moore
Mar 24, 2021·Journal of Computational Chemistry·Junichi HigoAtsushi Yoshimori
Dec 19, 2018·International Immunopharmacology·Jingnan AnXueguang Zhang
Apr 26, 2021·Pharmacology & Therapeutics·Mohammad Kaisarul Islam, Johnson Stanslas
May 13, 2021·ACS Infectious Diseases·Damir BojadzicPeter Buchwald
Jun 29, 2021·Frontiers in Oncology·María Paz SaldíasOscar Cerda
Jul 14, 2021·Life Sciences·Annoor AwadasseidWen Zhang
Aug 5, 2021·Nature Communications·Alexander BolaenderGabriela Chiosis
Sep 25, 2018·Journal of Medicinal Chemistry·Tianyu WangSheng Jiang
Nov 26, 2020·Analytical Chemistry·Salla ValtonenKari Kopra
Nov 12, 2020·Journal of Medicinal Chemistry·Celeste N AlverezKyung S Lee
Sep 3, 2020·ACS Omega·Suresh NarvaWen Zhang
Aug 31, 2021·RSC Chemical Biology·Lesley Ann Howell, Andrew Michael Beekman
Oct 1, 2021·Chemical Society Reviews·Jana VolarićBen L Feringa